Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

317
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
317
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

128
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
128

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Amyloid PET Quantitation and Centiloid Thresholds in the Diagnosis of Alzheimer Disease: An Individual Participant Data Meta-Analysis.

JAMA·2026
Same author

Inflammatory alterations mediate tau-associated neurodegeneration.

Brain communications·2026
Same author

Machine learning classification and regional differentiation of neuropathologically-confirmed Alzheimer's disease and comorbid Lewy body disease.

Communications medicine·2026
Same author

Elevated serotonin 1A receptor binding in borderline personality disorder co-morbid with major depressive episodes appears attributable to major depression alone.

Journal of psychiatric research·2026
Same author

Lower resting state functional connectivity between the hippocampus and default network is associated with suicidal ideation.

Journal of affective disorders·2026
Same author

Frequency of mixed neuropathologies in individuals with down syndrome with and without Alzheimer's dementia.

Acta neuropathologica·2026

Related Experiment Video

Updated: May 10, 2025

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
09:22

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

18.3K

Depressive Symptoms Correlate With Tau Accumulation Rates in Amyloid Positive Adults.

Daniel Talmasov1, Aubrey S Johnson2, Patrick J Brown3

  • 1Department of Neurology (DT, ASJ, FAP, PJL, KSM, ADNI), Columbia University Irving Medical Center, New York, NY; Department of Psychiatry (DT, PJB, JMM), Columbia University Irving Medical Center, New York, NY.

The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry
|April 25, 2025
PubMed
Summary

Depression is linked to faster tau buildup in the brain for individuals with Alzheimer's disease (AD) who are amyloid-positive. This suggests depression may indicate AD progression and warrants further research as a modifiable risk factor.

Keywords:
AV1451 Tau PETAlzheimer’s diseaseDepressionGeriatric Depression Scalelongitudinal PETneuropsychiatric inventorypositron emission tomography

More Related Videos

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

58
Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections
07:28

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections

Published on: May 19, 2022

3.6K

Related Experiment Videos

Last Updated: May 10, 2025

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
09:22

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

18.3K
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

58
Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections
07:28

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections

Published on: May 19, 2022

3.6K

Area of Science:

  • Neurodegenerative diseases
  • Alzheimer's disease research
  • Geriatric psychiatry

Background:

  • Depression is a common comorbidity in Alzheimer's disease (AD).
  • Depressive symptoms in AD are associated with accelerated cognitive decline and increased tau pathology.
  • Understanding the relationship between depression and AD biomarkers is crucial for disease management.

Purpose of the Study:

  • To investigate the association between depressive symptoms and the rate of tau accumulation in older adults.
  • To examine if Geriatric Depression Scale (GDS) scores correlate with tau accumulation in the temporal lobe.
  • To explore this relationship within the context of amyloid positivity in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort.

Main Methods:

  • Utilized data from 303 participants in the Alzheimer's Disease Neuroimaging Initiative (ADNI) database.
  • Assessed serial [18F]-flortaucipir tau positron-emission tomography (PET) scans from 2015-2022.
  • Correlated Geriatric Depression Scale (GDS) scores with annualized tau accumulation rates in temporal lobe regions, adjusting for covariates.

Main Results:

  • A positive correlation was found between Geriatric Depression Scale (GDS) scores and annualized tau accumulation rates.
  • This association was significant in amyloid-positive participants.
  • No significant correlation was observed in amyloid-negative participants.

Conclusions:

  • Depressive symptoms are associated with accelerated tau accumulation in amyloid-positive individuals with Alzheimer's disease.
  • Depression may serve as an indicator of Alzheimer's disease pathology progression.
  • Further research into depression as a modifiable risk factor for Alzheimer's disease is warranted.